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Purpose 
There is no consensus regarding a protective effect on mortality due to a cause other than cancer in 
patients treated with elective nephron sparing surgery relative to their radical nephrectomy 
counterparts. We test whether the protective effect of nephron sparing surgery relative to radical 
nephrectomy is universal or present in specific subgroups of patients. 
Materials and Methods 
A collaborative database of 5 institutions was queried to evaluate 1,783 patients without chronic 
kidney disease diagnosed with a clinical T1 renal mass that was treated with nephron sparing 
surgery or radical nephrectomy. Multivariable Cox regression analysis was done to assess the 
impact of surgery type (nephron sparing surgery vs radical nephrectomy) on other cause mortality 
after adjustment for patient and cancer characteristics. Interaction terms were used to test the 
hypothesis that the impact of surgery type varies according to specific subcohorts of patients. 
Results 
Ten-year other cause mortality-free survival rates were 90% and 88% after nephron sparing surgery 
and radical nephrectomy, respectively. In the overall population radical nephrectomy was not 
associated with an increased risk of other cause mortality on multivariable analysis compared to 
nephron sparing surgery (HR 0.91, 95% CI 0.6–1.38, p = 0.6). However, radical nephrectomy 
increased the risk of other cause mortality according to the increasing baseline Charlson 
comorbidity index (interaction test p = 0.0008). For example, in a patient with a Charlson 
comorbidity index of 4 the probability of 10-year other cause mortality-free survival was 86% after 
nephron sparing surgery and 60% after radical nephrectomy. 
Conclusions 
Elective nephron sparing surgery does not improve other cause survival relative to radical 
nephrectomy consistently in all patients with kidney cancer. Patients who are more ill with relevant 
comorbidities are those who benefit the most from nephron sparing surgery in terms of other cause 
mortality. 
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Nephron sparing surgery represents the standard of care for patients diagnosed with a cT1a renal 
mass.
1, 2, 3 and 4
 Similarly, NSS should be preferred over RN when technically feasible in patients 
diagnosed with a cT1b renal mass.
1, 2 and 4
 The rationale of these recommendations in favor of NSS 
is to decrease the risk of chronic kidney disease
5, 6 and 7
 as well as the risk of cardiovascular 
events
8 and 9
 while maintaining similar cancer control. 
However, the controlled comparison of NSS vs RN presented in the EORTC 30904 trial showed no 
difference with respect to cancer specific mortality but lower ACM after RN,
10
 implying a paradox 
advantage with respect to OCM after RN. Methodological limitations of this trial have been used to 
justify such a counterintuitive result and prompted further observational investigations that revealed 
the opposite finding, namely lower OCM after NSS relative to RN.
9, 11, 12, 13, 14 and 15
 Recently, the 
inherent risk of bias in such observational studies
9, 11, 12, 13, 14 and 15
 has been highlighted.
16 and 17
 It was 
postulated that if present, a beneficial effect of NSS on OCM has yet to be proved.
18
 
In this light the aim of the study was to examine the impact of surgery type, namely NSS vs RN, on 
the risk of OCM in a large multi-institutional study that allowed for adjustment for a detailed panel 
of intrinsic confounders such as BMI, CCI, and the presence and type of hypertension or diabetes. 
Our hypothesis stated that NSS might be associated with a lower risk of OCM and such a benefit 
might be more evident in specific subgroups of patients. 
Materials and Methods 
Study Population 
The current study relied on a collaborative database collected from 5 European tertiary care centers. 
Patients with a primary diagnosis of nonmetastatic clinical T1 unilateral kidney cancer without a 
baseline condition of chronic kidney disease treated with NSS or RN between 1984 and 2010 were 
included in analysis. 
Outcome 
The outcome of the study was OCM, defined as mortality due to a cause other than kidney cancer. 
Cause of death was defined according to death certificates. 
Covariates 
Covariates consisted of age at diagnosis, BMI, gender (male vs female), CCI,
19
 hypertension (no 
hypertension vs hypertension controlled by therapy vs hypertension uncontrolled by therapy), 
diabetes (present vs absent), clinical tumor size (based on preoperative imaging and defined as the 
greatest tumor diameter in mm) and year of surgery. 
Statistical Analyses 
Statistical analyses, and reporting and interpreting the results were done according to established 
guidelines
20
 and consisted of 4 steps. 1) The median and IQR or frequency and proportion are 
reported for continuous or categorical variables, respectively. The Mann-Whitney and chi-square 
tests were applied to compare the statistical significance of differences in the distribution of 
continuous or categorical variables, respectively. The Kaplan-Meier method was used to describe 
10-year OCM-free survival rates. 
2) Multivariable Cox regression analysis was done to assess the impact of surgery type on OCM 
after adjustment for all available covariates. The nonlinear nature of the relationship between each 
continuous predictor and the outcome was assessed by modeling each individual variable as a 
restricted cubic spline. However, no evidence of nonlinearity was recorded for each continuous 
term (each p >0.05). 
3) The hypothesis that the impact of surgery type was different by select patient subgroups was 
tested using an interaction term between treatment type (NSS vs RN) and each individual covariate. 
4) Cox regression derived coefficients were used to estimate the 10-year OCM-free survival 
probability. The locally weighted scatterplot smoothing method
21
 was used to graphically explore 
the probability of 10-year OCM-free survival after NSS or RN according to patient baseline 
characteristics (eg CCI) in compliance with established methodology.
22 and 23
 
All statistical tests were performed using RStudio®, version 0.98 for R, version 3.0.2 
(https://www.r-project.org/foundation/) with the packages Hmisc, stats, rms and graphics. All tests 
were 2-sided with significance considered at p <0.05. 
Results 
Patient Characteristics 
Overall, 1,783 patients were included in study (table 1). Patients were treated with NSS (56% or 
993) or RN (44% or 790). Patients treated with NSS were more frequently diagnosed with CCI 0 or 
greater (48% vs 39%, p <0.0001), any kind of hypertension (37% vs 29%, p = 0.0007), diabetes 
(10% vs 6%, p = 0.02) and smaller tumors (median clinical size 30 vs 47 mm, p <0.0001). 
Table 1.  
Descriptive characteristics of patients treated with NSS or RN for cT1 kidney cancer 
 
NSS RN p Value 
No. pts (%) 993 (56) 790 (44) – 
Median age (IQR) 61 (51–68) 61 (53–68) 0.2 
No. gender (%): 
  
0.3 
 
NSS RN p Value 
M 331 (33) 281 (36) 
 
F 662 (67) 509 (64) 
 
Median kg/m2 BMI (IQR) 26 (24–28) 26 (24–28) 0.3 
No. CCI (%): 
  
<0.0001 
0 516 (52) 484 (61) 
 
1 165 (17) 144 (18) 
 
2 197 (20) 99 (13) 
 
3 63 (6) 35 (4) 
 
4 or Greater 52 (5) 28 (4) 
 
No. hypertension (%): 
  
0.0007 
No 623 (63) 563 (71) 
 
Controlled by therapy 210 (21) 132 (17) 
 
Uncontrolled by therapy 160 (16) 95 (12) 
 
No. diabetes (%): 
  
0.02 
No 897 (90) 739 (94) 
 
Yes 96 (10) 51 (6) 
 
Median mm clinical size (IQR) 30 (20–38) 47 (35–58) <0.0001 
No. clinical stage (%): 
  
<0.0001 
cT1a 828 (83) 312 (39) 
 
cT1b 165 (17) 478 (61) 
 
No. diagnosis yr (%): 
  
<0.0001 
1984–1999 190 (19) 429 (54) 
 
2000–2004 255 (26) 164 (21) 
 
2005–2010 548 (55) 197 (25) 
 
Table options 
Survival 
Median followup among survivors was 70 months and 430 patients (27%) had more than 10 years 
of followup. Overall, 214 deaths were recorded during the study period, including 66 due to kidney 
cancer and 148 due to another cause. Ten-year OCM-free survival rates were 90% after NSS and 
88% after RN. 
Surgery Type Impact 
Overall Population 
On multivariable Cox regression analysis RN was not associated with an increased risk of OCM 
when compared to NSS (HR 0.91, 95% CI 0.6–1.38, p = 0.6, table 2). Of note, age (HR 1.09, 95% 
CI 1.07–1.11, p <0.0001) and CCI (HR 1.42, 95% CI 1.26–1.6, p = 0.0001) were associated with an 
increased risk of OCM. Conversely, female gender (HR 0.62, 95% CI 0.43–0.9) and year of 
diagnosis (HR 0.92, 95% CI 0.88–0.95, each p = 0.0001) were associated with a decreased risk of 
OCM. 
Table 2.  
Multivariable Cox regression analysis predicting OCM in patients treated with NSS or RN 
for cT1 kidney cancer 
Predictors HR (95% CI) p Value 
Surgery: 
  
NSS 1.00 (referent) – 
RN 0.91 (0.6–1.38) 0.6 
Age 1.09 (1.07–1.11) <0.0001 
BMI 0.99 (0.94–1.04) 0.6 
Gender: 
  
M 1.00 (referent) – 
F 0.62 (0.43–0.9) 0.01 
CCI 1.42 (1.26–1.6) <0.0001 
Hypertension: 
  
No 1.00 (referent) – 
Controlled by therapy 1.06 (0.65–1.71) 0.8 
Uncontrolled by therapy 0.69 (0.4–1.2) 0.2 
Diabetes: 
  
No 1.00 (referent) – 
Yes 0.61 (0.32–1.17) 0.1 
Tumor size 1.04 (0.91–1.18) 0.5 
Diagnosis yr 0.92 (0.88–0.95) <0.0001 
Table options 
Patient Subgroups 
The interaction tests for the hypothesis that the impact of surgery type on OCM varies according to 
age, BMI, gender, presence and type of hypertension, presence of diabetes, tumor size and year of 
diagnosis were not all statistically significant (p >0.05). Conversely, the interaction test for the 
hypothesis that the impact of surgery type on OCM varies according to patient baseline CCI was 
statistically significant (p = 0.0008). Specifically, when compared to NSS, RN increased the risk of 
OCM according to increasing baseline CCI. The adjusted probability of 10-year OCM-free survival 
after NSS or RN was plotted according to patient baseline CCI (see figure). For example, in patients 
with CCI 0 the probability of 10-year OCM-free survival was 95% after NSS and 94% after RN. In 
patients with CCI 2 the probability of 10-year OCM-free survival was 91% after NSS and 83% after 
RN. Finally, in patients with CCI 4 the probability of 10-year OCM-free survival was 86% after 
NSS and 60% after RN. 
 Probability of 10-year OCM-free survival after NSS or RN for cT1 kidney cancer according 
to baseline CCI (gray area) in 1,783 patients, including 993 treated with NSS and 790 
treated with RN for cT1 kidney cancer at total of 5 European tertiary care institutions from 
1984 to 2010. For example, in patients with CCI 0 probability of 10-year OCM-free survival 
was 95% after NSS and 94% after RN while in patients with CCI 4 probability was 86% and 
60%, respectively. 
Figure options 
Discussion 
Our hypothesis stated that NSS might be associated with a lower risk of OCM relative to RN and 
such a benefit might be more evident in specific subgroups of patients. To test this hypothesis we 
relied on a large, multi-institutional kidney cancer collaborative database collected at 5 European 
tertiary care institutions. 
Our results rejected the first statement of our hypothesis, namely that NSS might be associated with 
a lower risk of OCM in the overall population. It showed no difference between NSS and RN with 
respect to OCM after adjustment for all available potential confounders (HR 0.91, 95% CI 0.6–1.38, 
p = 0.6). Conversely, our results confirmed the second statement of our hypothesis, namely that 
NSS might be associated with a lower risk of OCM in a select subgroup of patients. The interaction 
test for the hypothesis that the impact of surgery type on OCM varies according to patient baseline 
CCI showed that relative to NSS RN increased the risk of OCM according to increasing baseline 
CCI (p = 0.0008). This indicates that individuals who are more ill are those who maximally benefit 
from the choice of NSS (see figure). Specifically, a patient with several comorbidities (CCI 4) 
harbors a 10-year OCM-free survival probability of 86% after NSS and 60% after RN. Therefore, 
NSS should be strongly considered in patients who are more ill. On the other hand, a patient 
without comorbidities (CCI 0) harbors a 10-year OCM-free survival probability of 95% after NSS 
and 94% after RN. Such a marginal risk reduction provides weaker arguments for selecting NSS 
over RN. 
These findings are not negligible with respect to clinical decision making since contemporary 
indications
1, 2 and 3
 supporting NSS over RN suffer from a lack of consensus about the potential 
OCM benefit of NSS over RN.
4, 13 and 18
 Moreover, our results represent another essential piece of 
the puzzle regarding the impact of NSS on noncancer specific survival among individuals 
diagnosed with a cT1 renal mass. 
When compared to NSS in a randomized, controlled study,
10
 RN resulted in similar cancer specific 
mortality and similar if not lower ACM rates. However, the unmet accrual end point and the 
important contamination rates between the trial arms bounded the clinical applicability of this 
finding. When compared to NSS in retrospective, observational, population based studies,
9, 11, 
12 and 13
 RN resulted in higher ACM and OCM rates. However, more recent analyses of the same 
SEER (Surveillance, Epidemiology and End Results)-Medicare database showed that patients 
treated with RN achieved ACM-free survival comparable to that of their noncancer controls.
16
 
Surprisingly, patients treated with NSS achieved superior ACM-free survival than noncancer 
controls, highlighting the risk of a biased conclusion when these surgery types are compared in a 
population based setting. 
Notably, the current study partially reconciles such contradictory findings. Our results showed that 
NSS does not confer an OCM benefit in the overall population diagnosed with a cT1 renal mass but 
NSS translates into an OCM benefit in a select subgroup of individuals, specifically patients who 
are more fragile due to relevant comorbidities. This observation might explain the opposite results 
in the EORTC 30904 trial
10
 and the Medicare based studies
9, 11, 12 and 13
 since the latter invariably 
relied on patients 65 years old or older and who were in consequence more ill by definition. 
Moreover, the current analysis also corroborates many other findings reported in other studies with 
different designs. 1) The survival benefit associated with NSS was greatest in patients with a CCI of 
1 or higher as also noted on subgroup analyses in a previous population based study.
11
 
2) Prospective
5
 and retrospective
6 and 13
 studies showed superior renal function outcomes after NSS 
relative to RN and specifically a differential effect of NSS with respect to protection from 
postoperative CKD according to baseline renal function.
24
 Likewise, patients without comorbidities 
might better tolerate the renal function detriment due to RN. In consequence, in healthier 
individuals the survival benefit of nephron sparing is masked. On the contrary, patients with 
relevant comorbidities might experience a greater renal function detriment due to RN. In 
consequence, in individuals who are more ill the survival benefit of nephron sparing is highlighted. 
Similarly, NSS has been associated with lower rates of cardiovascular events than RN.
8
 
Accordingly, it is possible that the burden of postoperative cardiovascular events is heavy enough to 
translate into OCM sequelae in more ill and more fragile patients, and it is lighter in healthier and 
more robust patients. 
3) Finally, lower OCM-free survival in cases of chronic kidney disease due to medical etiology 
relative to surgically induced chronic kidney disease has been observed in other studies.
25, 26 and 27
 
Those findings validate the existence of a link between the general and the renal health status of the 
patient at baseline and the relative impact of nephron loss on the risk of OCM recorded in the 
current report. 
It is important to remember that due to technical differences NSS is intrinsically associated with a 
higher risk of perioperative complication when compared to RN.
28 and 29
 Also, the presence of 
comorbidities represents an established risk factor for surgical and medical complications following 
NSS.
23
 Accordingly, when NSS is contemplated in patients with comorbidities, the OCM benefit 
demonstrated in the current study should be balanced with a potentially higher morbidity profile. 
Nonetheless, in the current series the overall 90-day mortality rate was extremely low at 0.3% (data 
not shown) and no difference was recorded after either treatment modality (unadjusted HR 6.22, p = 
0.1, data not shown). This observation corroborates previous investigations,
28 and 29
 suggesting that 
the reported difference with respect to perioperative morbidity does not translate into a similar 
difference with respect to perioperative mortality. In consequence, a higher risk of perioperative 
complications might be worth exchanging for a potential long-term survival benefit. 
The current study has several strengths, including multi-institutional design, detailed information on 
the baseline cardiovascular and comorbidity profile of the patients, and inclusion of patients without 
baseline chronic kidney disease. However, despite its appeal and uniqueness the current study is not 
devoid of limitations. First and foremost, a significant limitation is related to the retrospective 
design of the study, which could not exclude residual confounders even after adjustment for patient 
and cancer characteristics.
30
 Recently, the risk of selection bias favoring NSS in population based 
studies
16
 was highlighted by the presence of an ACM advantage after NSS relative to RN.
13
 It is 
possible that, given the institutional nature of our report and the availability of a detailed panel of 
preoperative information, such biases are less relevant if not nonoperational in the current study. 
Accordingly, no difference was recorded after RN relative to NSS with respect to ACM (adjusted 
HR 1.12, p = 0.5, data not shown). 
Finally, although our results demonstrated that CCI significantly affects the OCM survival benefit 
following NSS, our analysis did not identify which specific comorbidities should be evaluated for 
clinical decision making. The potential risk of a subjective CCI calculation represents an additional 
limitation of our comorbidities definition. In this light identifying the particular baseline health 
conditions that could specify the indications for NSS are yet to be investigated. 
Nevertheless, despite these limitations the findings of the current study require special 
consideration. For the first time to our knowledge a specific group of patients who benefited from 
the choice of NSS over RN in terms of noncancer related survival was identified. Moreover, the 
information that individuals with normal preoperative renal function but who are more ill due to 
other comorbidities are those who maximally benefit from NSS is of the utmost importance for 
clinical decision making and trial planning. 
Conclusions 
The impact of NSS on the risk of noncancer specific mortality is not equal in all patients with 
normal preoperative renal function who are diagnosed with a cT1 renal mass. Specifically, in 
healthier patients without comorbidities NSS does not decrease the risk of OCM relative to RN. 
Conversely, in patients who are more ill with relevant comorbidities NSS significantly decreases the 
risk of OCM relative to RN. 
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